Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Pediatr Blood Cancer. 2009 Dec 15;53(7):1227-30. doi: 10.1002/pbc.22141.

PARP1 expression in pediatric central nervous system tumors.

Author information

  • 1Department of Pediatrics, Anschutz Medical Campus, University of Colorado Denver, Aurora, Colorado, USA. valerie.barton@ucdenver.edu

Abstract

BACKGROUND:

Despite advances in therapy, outcome in many high-grade pediatric central nervous system (CNS) tumors remains poor. The focus of neuro-oncology research has thus turned towards identifying novel therapeutic targets. Poly(ADP-ribose) polymerase-1 (PARP1) is a DNA repair protein that has been studied in a variety of malignancies and may interfere with therapy-induced DNA damage, however expression in pediatric CNS tumors is unknown.

PROCEDURE:

We evaluated PARP1 mRNA expression in 81 pediatric CNS tumors using microarray technology. Protein expression was examined by Western blot.

RESULTS:

PARP1 mRNA is highly expressed in high-grade tumors (P < 0.0001). PARP1 mRNA expression was greater in high-grade glioma than pilocytic astrocytoma (P = 3.5 x 10(-5)) and in large cell medulloblastoma over classic medulloblastoma (P = 0.0053). PARP1 protein was also prominent in high-grade tumors (P = 0.022).

CONCLUSION:

These findings indicate that PARP1 is expressed in high-grade pediatric CNS tumors, implicating PARP1 inhibition as a potential therapeutic target.

(c) 2009 Wiley-Liss, Inc.

PMID:
19533660
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for John Wiley & Sons, Inc.
    Loading ...
    Write to the Help Desk